Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-25-029464
Filing Date
2025-04-07
Accepted
2025-04-07 16:58:10
Documents
98
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 ANNUAL REPORT ea0237295-20f_neuro.htm   iXBRL 20-F 2006988
2 AMENDED AND RESTATED ARTICLES OF ASSOCIATION ea023729501ex1-1_neuro.htm EX-1.1 285033
3 DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF ea023729501ex2-1_neuro.htm EX-2.1 55440
4 2018 SHARE INCENTIVE PLAN ea023729501ex4-2_neuro.htm EX-4.2 147637
5 INSIDER TRADING POLICY ea023729501ex11-1_neuro.htm EX-11.1 82866
6 CERTIFICATION ea023729501ex12-1_neuro.htm EX-12.1 9989
7 CERTIFICATION ea023729501ex12-2_neuro.htm EX-12.2 10146
8 CERTIFICATION ea023729501ex13-1_neuro.htm EX-13.1 3429
9 CERTIFICATION ea023729501ex13-2_neuro.htm EX-13.2 3529
10 CONSENT OF SOMEKH CHAIKIN (MEMBER FIRM OF KPMG INTERNATIONAL), INDEPENDENT REGIS ea023729501ex15-1_neuro.htm EX-15.1 2137
11 GRAPHIC image_001.jpg GRAPHIC 13938
  Complete submission text file 0001213900-25-029464.txt   8314667

Data Files

Seq Description Document Type Size
12 XBRL SCHEMA FILE nrsn-20241231.xsd EX-101.SCH 60639
13 XBRL CALCULATION FILE nrsn-20241231_cal.xml EX-101.CAL 40413
14 XBRL DEFINITION FILE nrsn-20241231_def.xml EX-101.DEF 309437
15 XBRL LABEL FILE nrsn-20241231_lab.xml EX-101.LAB 539980
16 XBRL PRESENTATION FILE nrsn-20241231_pre.xml EX-101.PRE 320441
101 EXTRACTED XBRL INSTANCE DOCUMENT ea0237295-20f_neuro_htm.xml XML 755009
Mailing Address 11 HAMENOFIM ST. BUILDING B HERZLIYA L3 4672562
Business Address 11 HAMENOFIM ST. BUILDING B HERZLIYA L3 4672562 972-9-9531142
NeuroSense Therapeutics Ltd. (Filer) CIK: 0001875091 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 20-F | Act: 34 | File No.: 001-41084 | Film No.: 25818843
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)